Radiotherapy and Oncology · 2015 · 64 citations · 20 references
MedicineOncologyPharmacoeconomicsCost-effectiveness AnalysisGenitourinary Radiation OncologyUrologic OncologyGenitourinary Cancer RadiotherapyRadiation TherapyRadiation Therapy For Prostate DiseaseRadiation ToxicityRadiobiological ConsiderationsRadiobiological ModelingCost-effectivenessIntensity-modulated Radiation Therapy EffectsOncologic Outcomes AssessmentProstate Cancer RadiotherapyQuality-adjusted Life Year ModelingRectal Spacer UseRectal ToxicityTreatment-related Complication Costs
BACKGROUND AND PURPOSE: To compare the cost-effectiveness of treating prostate cancer patients with intensity-modulated radiation therapy and a spacer (IMRT+S) versus IMRT-only without a spacer (IMRT-O). MATERIALS AND METHODS: A decision-analytic Markov model was constructed to examine the effect of late rectal toxicity and compare the costs and quality-adjusted Life Years (QALYs) of IMRT-O and IMRT+S. The main assumption of this modeling study was that disease progression, genito-urinary toxicity and survival were equal for both comparators. RESULTS: For all patients, IMRT+S revealed a lower toxicity than IMRT-O. Treatment follow-up and toxicity costs for IMRT-O and IMRT+S amounted to €1604 and €1444, respectively, thus saving €160 on the complication costs at an extra charge of €1700 for the spacer in IMRT+S. The QALYs yielded for IMRT-O and IMRT+S were 3.542 and 3.570, respectively. This results in an incremental cost-effectiveness ratio (ICER) of €55,880 per QALY gained. For a ceiling ratio of €80,000, IMRT+S had a 77% probability of being cost-effective. CONCLUSION: IMRT+S is cost-effective compared to IMRT-O based on its potential to reduce radiotherapy-related toxicity.
20
Costs, effects and C/E‐ratios alongside a clinical trial
Ben A. van Hout, Maiwenn Al, Gilad S. Gordon et al. · Health Economics · 1994 · 981 citations
Michael J. Zeléfsky, Emily J. Levin, Margie Hunt et al. · International Journal of Radiation Oncology*Biology*Physics · 2008 · 738 citations · Full text
Time Course and Predictors of Symptoms After Primary Prostate Cancer Therapy
James A. Talcott, Judith Manola, Jack A. Clark et al. · Journal of Clinical Oncology · 2003 · 226 citations